Underlying Ossification Phenotype in a Murine Model of Metastatic Synovial Sarcoma

Int J Mol Sci. 2020 Apr 10;21(7):2636. doi: 10.3390/ijms21072636.

Abstract

Synovial sarcoma, an uncommon cancer, typically affects young adults. Survival rates range from 36% to 76%, decreasing significantly when metastases are present. Synovial sarcomas form in soft tissues, often near bones, with about 10% demonstrating ossification in the tumor. The literature is inconclusive on whether the presence of ossification portends a worse prognosis. To this end, we analyzed our genetic mouse models of synovial sarcoma to determine the extent of ossification in the tumors and its relationship with morbidity. We noted higher ossification within our metastatic mouse model of synovial sarcoma. Not only did we observe ossification within the tumors at a frequency of 7%, but an even higher frequency, 72%, of bone reactivity was detected by radiography. An enrichment of bone development genes was associated with primary tumors, even in the absence of an ossification phenotype. In spite of the ossification being intricately linked with the metastatic model, the presence of ossification was not associated with a faster or worse morbidity in the mice. Our conclusion is that both metastasis and ossification are dependent on time, but that they are independent of one another.

Keywords: bone development genes; heterotopic ossification; inflammation; intralesional calcification; metastasis; parathyroid hormone-like hormone; synovial sarcoma.

MeSH terms

  • Animals
  • Biomarkers, Tumor
  • Biopsy
  • Bone and Bones / metabolism
  • Disease Models, Animal
  • Gene Expression Profiling
  • Gene Fusion
  • Genotype
  • Humans
  • Immunohistochemistry
  • Kaplan-Meier Estimate
  • Mice
  • Neoplasm Metastasis
  • Ossification, Heterotopic*
  • Phenotype*
  • Prognosis
  • Sarcoma, Synovial / etiology
  • Sarcoma, Synovial / metabolism
  • Sarcoma, Synovial / mortality
  • Sarcoma, Synovial / pathology*

Substances

  • Biomarkers, Tumor